ALCON AG

NYSE: ALC (Alcon Inc.)

Last update: 02 Oct, 4:08PM

75.11

0.00 (0.00%)

Previous Close 75.11
Open 75.58
Volume 2,092,647
Avg. Volume (3M) 2,020,360
Market Cap 37,134,385,152
Price / Earnings (TTM) 34.77
Price / Earnings (Forward) 20.96
Price / Sales 3.73
Price / Book 1.68
52 Weeks Range
73.22 (-2%) — 99.30 (32%)
Earnings Date 11 Nov 2025
TTM Dividend Yield 0.35%
Profit Margin 11.28%
Operating Margin (TTM) 13.30%
Diluted EPS (TTM) 2.25
Quarterly Revenue Growth (YOY) 0.60%
Quarterly Earnings Growth (YOY) 41.10%
Total Debt/Equity (MRQ) 23.63%
Current Ratio (MRQ) 2.70
Operating Cash Flow (TTM) 2.12 B
Levered Free Cash Flow (TTM) 1.18 B
Return on Assets (TTM) 2.74%
Return on Equity (TTM) 5.23%

Market Trend

Short Term Medium Term
Industry Medical Instruments & Supplies (US) Mixed Mixed
Medical Instruments & Supplies (Global) Mixed Bearish
Stock Alcon Inc. Bearish Bearish

AIStockmoo Score

2.0
Analyst Consensus 3.0
Insider Activity NA
Price Volatility 5.0
Technical Moving Averages 2.5
Technical Oscillators -2.5
Average 2.00

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
ALC 37 B 0.35% 34.77 1.68
RMD 40 B 0.39% 28.53 6.77
STVN 7 B 0.21% 44.79 4.39
BDX 54 B 1.11% 34.21 2.16
WST 16 B 0.28% 34.84 6.71
AVTR 8 B - 12.33 1.49

Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.

Sector Healthcare
Industry Medical Instruments & Supplies
Investment Style Large Core
% Held by Insiders 0.13%
% Held by Institutions 68.26%

Ownership

Name Date Shares Held
Zurcher Kantonalbank (Zurich Cantonalbank) 30 Jun 2025 9,142,139
52 Weeks Range
73.22 (-2%) — 99.30 (32%)
Price Target Range
77.53 (3%) — 110.00 (46%)
High 110.00 (Mizuho, 46.45%) Buy
Median 91.00 (21.16%)
Low 77.53 (JP Morgan, 3.22%) Hold
Average 91.61 (21.97%)
Total 5 Buy, 4 Hold
Avg. Price @ Call 77.91
Firm Date Target Price Call Price @ Call
BTIG 13 Oct 2025 91.00 (21.16%) Buy 72.60
Barclays 13 Oct 2025 86.00 (14.50%) Hold 72.60
Stifel 29 Sep 2025 85.00 (13.17%) Buy 74.11
21 Aug 2025 90.00 (19.82%) Buy 79.18
Baird 21 Aug 2025 95.00 (26.48%) Buy 79.18
JP Morgan 21 Aug 2025 77.53 (3.22%) Hold 79.18
Mizuho 21 Aug 2025 110.00 (46.45%) Buy 79.18
Morgan Stanley 21 Aug 2025 80.00 (6.51%) Hold 79.18
Needham 20 Aug 2025 107.00 (42.46%) Buy 81.04
13 Aug 2025 107.00 (42.46%) Buy 86.48
Wells Fargo 06 Aug 2025 93.00 (23.82%) Hold 84.12
Show more

No data within this time range.

Date Type Details
17 Oct 2025 Announcement Broadwood Partners Issues Letter to STAAR Surgical’s Board Urging it to Allow Timely Shareholder Vote on Alcon Sale
15 Oct 2025 Announcement Broadwood Partners: All Three Leading Proxy Advisory Firms Recommend STAAR Surgical Shareholders Vote “AGAINST” Sale to Alcon
14 Oct 2025 Announcement Broadwood Partners Comments on STAAR Surgical’s Late and Troubling Disclosure in Deeply Flawed Sale Process to Alcon
10 Oct 2025 Announcement Broadwood Partners Issues Letter to STAAR Surgical’s Board Questioning Its Diligence in Rush to Reaffirm Support for Alcon Sale
08 Oct 2025 Announcement Broadwood Partners Questions Integrity of STAAR Surgical’s Last-Minute Forecast Change and Fairness Opinion in Sale to Alcon
08 Oct 2025 Announcement STAAR Surgical Board of Directors Reiterates Unanimous Recommendation that STAAR Stockholders Vote “FOR” the Alcon Merger Agreement on WHITE Proxy Card
08 Oct 2025 Announcement Broadwood Partners: Leading Advisory Firm Glass Lewis Urges STAAR Shareholders to Vote “AGAINST” Sale to Alcon
07 Oct 2025 Announcement Defender Capital Opposes STAAR Surgical's Proposed Sale to Alcon
06 Oct 2025 Announcement Broadwood Partners Issues Letter to STAAR Surgical’s Board Questioning Its Judgment in Proposed Sale to Alcon
06 Oct 2025 Announcement Yunqi Capital, One of STAAR Surgical Company’s Largest Shareholders, Reiterates Its Opposition to the Proposed Merger with Alcon
03 Oct 2025 Announcement Broadwood Partners Publishes Presentation Detailing Opposition to STAAR Surgical’s Sale to Alcon
30 Sep 2025 Announcement Alcon and STAAR Surgical Announce Expiration of Hart-Scott-Rodino Waiting Period for Alcon’s Acquisition of STAAR
24 Sep 2025 Announcement Broadwood Partners Files Definitive Proxy Statement Soliciting STAAR Surgical Stockholders to Vote “AGAINST” Proposed Acquisition by Alcon
22 Sep 2025 Announcement STAAR Surgical Announces Expiration of “Window Shop” Period; No Competing Acquisition Proposals Received
22 Sep 2025 Announcement Yunqi Capital, 5.1% Holder and One of STAAR Surgical Company’s Largest Shareholders, Announces Intention to Vote Against the Proposed Sale to Alcon
16 Sep 2025 Announcement STAAR Surgical Board of Directors Unanimously Believes Alcon Merger Maximizes Value for STAAR Stockholders
16 Sep 2025 Announcement Alcon Announces New Time and Motion Study Results Supporting Superior Efficiency* for Cataract and Vitreoretinal Surgery with UNITY VCS
08 Sep 2025 Announcement Alcon Launches Groundbreaking Innovations and Highlights New Study Findings at ESCRS 2025
26 Aug 2025 Announcement Alcon to Present at 2025 Baird Global Healthcare Conference
19 Aug 2025 Announcement Alcon Reports Second-Quarter 2025 Results, Launched Tryptyr and Announced Acquisition of STAAR Surgical
18 Aug 2025 Announcement Alcon Underscores Benefits of Its IOLs and Cataract Surgical Equipment at APACRS
05 Aug 2025 Announcement Alcon Agrees to Acquire STAAR Surgical
Show more
TTM Dividend Yield 0.35%
4Y Average Dividend Yield 0.26%
Payout Ratio 11.81%
Ex Date Announcement Date Payment Date Details
14 May 2024 08 Apr 2024 16 May 2024 0.2644 Cash
10 May 2023 30 Mar 2023 12 May 2023 0.2356 Cash
29 Apr 2022 24 Mar 2022 05 May 2022 0.2083 Cash
04 May 2021 24 Mar 2021 06 May 2021 0.0909 Cash

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2024 0.264 1 0.31
2023 0.236 1 0.30
2022 0.208 1 0.30
2021 0.091 1 0.10

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria